


CLAIMS:

1. The use of a compound of the formula I:



(I)

wherein:

ring C is a 5-6-membered heterocyclic moiety which may be saturated or unsaturated, which may be aromatic or non-aromatic, and which contains 1-3 heteroatoms selected independently from O, N and S;

Z is -O-, -NH-, -S- or -CH₂-;

R¹ represents hydrogen, C₁₋₄alkyl, C₁₋₄alkoxymethyl, di(C₁₋₄alkoxy)methyl, C₁₋₄alkanoyl, trifluoromethyl, cyano, amino, C₂₋₃alkenyl, C₂₋₃alkynyl, a phenyl group, a benzyl group or a 5-6-membered heterocyclic group with 1-3 heteroatoms, selected independently from O, S and N, which heterocyclic group may be aromatic or non-aromatic and may be saturated (linked via a ring carbon or nitrogen atom) or unsaturated (linked via a ring carbon atom), and which phenyl, benzyl or heterocyclic group may bear on one or more ring carbon atoms up to 5 substituents selected from hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C₂₋₄alkanoyl, C₁₋₄alkanoylamino, C₁₋₄alkoxycarbonyl, C₁₋₄alkylsulphanyl, C₁₋₄alkylsulphinyl, C₁₋₄alkylsulphonyl, carbamoyl, N-C₁₋₄alkylcarbamoyl, N,N-di(C₁₋₄alkyl)carbamoyl, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl, N,N-di(C₁₋₄alkyl)aminosulphonyl, C₁₋₄alkylsulphonylamino, C₁₋₄alkylamino, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄haloalkyl, C₁₋₄hydroxyalkoxy, carboxy and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2

substituents selected from oxo, hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkanoyloxy, trifluoromethyl, cyano, amino, nitro and C₁₋₄alkoxycarbonyl; and additionally R¹ may represent carboxy, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₃alkyl, or phenylC₂₋₄alkyl wherein the phenyl moiety may bear up to 5 substituents selected from the list herein defined for a phenyl ring which is directly linked to ring C:

n is an integer from 0 to 5;

m is an integer from 0 to 3;

R² represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylsulphanyl, -NR³R⁴ (wherein R³ and R⁴, which may be the same or different, each represents hydrogen or C₁₋₃alkyl), or R⁵X¹- (wherein X¹ represents a direct bond, -O-, -CH₂-, -OCO-, carbonyl-, -S-, -SO-, -SO₂-, -NR⁶CO-, -CONR⁷-, -SO₂NR⁸-, -NR⁹SO₂- or -NR¹⁰- (wherein R⁶, R⁷, R⁸, R⁹ and R¹⁰ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl), and R⁵ is selected from one of the following eighteen groups:

1) hydrogen or C₁₋₃alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino;

2) C₁₋₃alkylX²COR¹¹ (wherein X² represents -O- or -NR¹²- (in which R¹² represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R¹¹ represents C₁₋₃alkyl, -NR¹³R¹⁴ or -OR¹⁵ (wherein R¹³, R¹⁴ and R¹⁵ which may be the same or different each represents hydrogen, C₁₋₃alkyl, C₄₋₅alkyl or C₁₋₃alkoxyC₂₋₃alkyl));

3) C₁₋₃alkylX³R¹⁶ (wherein X³ represents -O-, -S-, -SO-, -SO₂-, -OCO-, -NR¹⁷CO-, -CONR¹⁸-, -SO₂NR¹⁹-, -NR²⁰SO₂- or -NR²¹- (wherein R¹⁷, R¹⁸, R¹⁹, R²⁰ and R²¹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R¹⁶ represents hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl or a 5-6-membered saturated heterocyclic group with 1-2

heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2

substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄cyanoalkyl and C₁₋₄alkoxycarbonyl);

4) C₁₋₃alkylX⁴C₁₋₃alkylX⁵R²² (wherein X⁴ and X⁵ which may be the same or different are each -O-, -S-, -SO-, -SO₂-, -NR²³CO-, -CONR²⁴-, -SO₂NR²⁵-, -NR²⁶SO₂- or -NR²⁷- (wherein R²³, R²⁴,


R²⁵, R²⁶ and R²⁷ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²² represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl);

Sub
B1

Pub No. 99/03295

18) C_{1-3} alkyl R^{54} C_{1-3} alkyl X^9R^{55} (wherein X^9 is as defined herein and R^{54} and R^{55} are each independently selected from hydrogen, C_{1-3} alkyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3} alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4} alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-4} alkyl, C_{1-4} hydroxyalkyl, C_{1-4} alkoxy, C_{1-4} cyanoalkyl and C_{1-4} alkoxycarbonyl), with the proviso that R^{54} cannot be hydrogen; and additionally wherein any C_{1-3} alkyl, C_{2-3} alkenyl or C_{2-3} alkynyl group in R^5X^1 may bear one or more substituents selected from hydroxy, halogeno and amino; or a salt thereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals such as humans.

2. The use of a compound of the formula Ia:




(Ia)

wherein:

ring C, R^1 , R^2 , n and Z are as defined in claim 1 with the proviso that R^2 is not hydrogen; and R^{2a} represents hydrogen, halogeno, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkylthio, $-NR^{3a}R^{4a}$ (wherein R^{3a} and R^{4a} , which may be the same or different, each represents hydrogen or C_{1-3} alkyl), or $R^{5a}(CH_2)_{za}X^{1a}$ (wherein R^{5a} is a 5- or 6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-4} alkyl, C_{1-4} hydroxyalkyl and C_{1-4} alkoxy, za is an integer from 0 to 4 and X^{1a} represents a direct bond, $-O-$, $-CH_2-$, $-S-$, $-SO-$, $-SO_2-$, $-NR^{6a}CO-$, $-CONR^{7a}-$, $-SO_2NR^{8a}-$, $-NR^{9a}SO_2-$ or $-NR^{10a}-$ (wherein R^{6a} , R^{7a} , R^{8a} , R^{9a} and R^{10a} each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl));

or a salt thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals such as humans.

3. The use of a compound of the formula Ib:



(Ib)

wherein:

ring C, R¹, R² and n are as defined in claim 1 with the proviso that R² is not hydrogen, R^{2a} is as defined in claim 2; and

Zb is -O- or -S-;


or a salt thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals such as humans.

4. A compound of the formula II:

25

Sub
Bl

[illegible]



(II)

wherein:

10 ring C , R^1 , R^2 and n are as defined in claim 1 with the proviso that R^2 does not have any of the following values:

hydrogen, substituted or unsubstituted C₁₋₃alkyl, halogeno, C₁₋₃alkoxy, phenoxy or phenylC₁₋₃alkoxy;

R^{2a} is as defined in claim 2; and

15 Zb is as defined in claim 3:

or a salt thereof.

5. A compound as claimed in claim 4 wherein Zb is -O-

20 6. A compound as claimed in claim 4 or claim 5 wherein R^{2a} is methoxy.

7. A compound as claimed in any one of claims 4-6 wherein ring C is a 5-membered heteroaromatic moiety which contains 1-3 heteroatoms selected independently from O, N and S.

8. A compound as claimed in any one of claims 4-7 wherein R¹ is a phenyl group or a 5-6-membered heteroaromatic group with 1-3 heteroatoms, selected independently from O, S and N, (linked via a ring carbon atom), which phenyl or heteroaromatic group is optionally substituted as defined in claim 1.

[illegible]

code	description	code	description
0000	no error	0000	no error
0001	error	0001	error
0002	error	0002	error
0003	error	0003	error
0004	error	0004	error
0005	error	0005	error
0006	error	0006	error
0007	error	0007	error
0008	error	0008	error
0009	error	0009	error
0010	error	0010	error
0011	error	0011	error
0012	error	0012	error
0013	error	0013	error
0014	error	0014	error
0015	error	0015	error
0016	error	0016	error
0017	error	0017	error
0018	error	0018	error
0019	error	0019	error
0020	error	0020	error
0021	error	0021	error
0022	error	0022	error
0023	error	0023	error
0024	error	0024	error
0025	error	0025	error
0026	error	0026	error
0027	error	0027	error
0028	error	0028	error
0029	error	0029	error
0030	error	0030	error
0031	error	0031	error
0032	error	0032	error
0033	error	0033	error
0034	error	0034	error
0035	error	0035	error
0036	error	0036	error
0037	error	0037	error
0038	error	0038	error
0039	error	0039	error
0040	error	0040	error
0041	error	0041	error
0042	error	0042	error
0043	error	0043	error
0044	error	0044	error
0045	error	0045	error
0046	error	0046	error
0047	error	0047	error
0048	error	0048	error
0049	error	0049	error
0050	error	0050	error
0051	error	0051	error
0052	error	0052	error
0053	error	0053	error
0054	error	0054	error
0055	error	0055	error
0056	error	0056	error
0057	error	0057	error
0058	error	0058	error
0059	error	0059	error
0060	error	0060	error
0061	error	0061	error
0062	error	0062	error
0063	error	0063	error
0064	error	0064	error
0065	error	0065	error
0066	error	0066	error
0067	error	0067	error
0068	error	0068	error
0069	error	0069	error
0070	error	0070	error
0071	error	0071	error
0072	error	0072	error
0073	error	0073	error
0074	error	0074	error
0075	error	0075	error
0076	error	0076	error
0077	error	0077	error
0078	error	0078	error
0079	error	0079	error
0080	error	0080	error
0081	error	0081	error
0082	error	0082	error
0083	error	0083	error
0084	error	0084	error
0085	error	0085	error
0086	error	0086	error
0087	error	0087	error
0088	error	0088	error
0089	error	0089	error
0090	error	0090	error
0091	error	0091	error
0092	error	0092	error
0093	error	0093	error
0094	error	0094	error
0095	error	0095	error
0096	error	0096	error
0097	error	0097	error
0098	error	009	

Sub
p2

25

30

9. A compound as claimed in any one of claims 4-8 wherein R² represents hydroxy, halogeno, nitro, trifluoromethyl, C₁₋₃alkyl, cyano, amino or R⁵X¹- [wherein X¹ is as defined in claim 1 and R⁵ is selected from one of the following eighteen groups:

- 1) C₁₋₄alkyl which may be unsubstituted or substituted with one or more fluorine atoms, or C₂₋₄alkyl which may be unsubstituted or substituted with 1 or 2 groups selected from hydroxy and amino;

- 2) ~~C₂₋₃alkylX²COR¹¹ (wherein X² is as defined in claim 1 and R¹¹ represents -NR¹³R¹⁴ or -OR¹⁵ (wherein R¹³, R¹⁴ and R¹⁵ which may be the same or different are each C₁₋₃alkyl or C₁₋₃alkoxyethyl));~~

- 3) C₂₋₄alkylX³R¹⁶ (wherein X³ is as defined in claim 1 and R¹⁶ is a group selected from C₁₋₃alkyl, cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl which group is linked to X³ through a carbon atom and which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₂alkoxy and which cyclopentyl, cyclohexyl, pyrrolidinyl or piperidinyl group may carry one substituent selected from oxo, hydroxy, halogeno, C₁₋₂alkyl, C₁₋₃hydroxyalkyl and C₁₋₃alkoxy);

- 4) $C_{2,3}alkylX^4C_{2,3}alkylX^5R^{22}$ (wherein X^4 and X^5 are as defined in claim 1 and R^{22} represents hydrogen or $C_{1,3}alkyl$);

- 5) C₁₋₄alkylR⁵⁹ (wherein R⁵⁹ is a group selected from pyrrolidinyl, piperazinyl, piperidinyl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl and 1,3-dithian-2-yl, which group is linked to C₁₋₄alkyl through a carbon atom and which group may carry 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃hydroxyalkyl, C₁₋₃alkoxy, C₁₋₂alkoxyC₁₋₃alkyl and C₁₋₂alkylsulphonylC₁₋₃alkyl) or C₂₋₄alkylR⁶⁰ (wherein R⁶⁰ is a group selected from morpholino, thiomorpholino, pyrrolidin-1-yl, piperazin-1-yl and piperidino which group may carry 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃hydroxyalkyl, C₁₋₃alkoxy, C₁₋₂alkoxyC₁₋₃alkyl and C₁₋₃alkylsulphonylC₁₋₃alkyl);

- 6) C₃₋₄alkenylR⁶¹ (wherein R⁶¹ represents R⁵⁹ or R⁶⁰ as defined herein);

- 7) C₃₋₄alkynylR⁶¹ (wherein R⁶¹ represents R⁵⁹ or R⁶⁰ as defined herein);

- 8) R^{29} (wherein R^{29} is as defined in claim 1);

- 9) C₁₋₄alkylR²⁹ (wherein R²⁹ is as defined in claim 1);

- 10) 1-R²⁹prop-1-en-3-yl or 1-R²⁹but-2-en-4-yl (wherein R²⁹ is as defined in claim 1 with the proviso that when R⁵ is 1-R²⁹prop-1-en-3-yl, R²⁹ is linked to the alkenyl group via a carbon atom);

10. A compound as claimed in any one of claims 4-9 wherein R² represents 2-methoxyethoxy, 2-(2-methoxyethoxy)ethoxy, 3-methoxypropoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-(tetrahydropyran-4-yloxy)ethoxy, 3-(tetrahydropyran-4-yloxy)propoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(imidazol-1-yl)ethoxy, 3-(imidazol-1-yl)propoxy, 2-(1,1-dioxothiomorpholino)ethoxy, 3-(1,1-dioxothiomorpholino)propoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, 2-(N-methoxyacetyl-N-methylamino)ethoxy, 3-(N-methoxyacetyl-N-methylamino)propoxy, N-methylpiperidin-3-ylmethoxy, 4-(pyrrolidin-1-yl)but-2-en-yloxy, 2-(2-oxopyrrolidin-1-yl)ethoxy, 3-(2-oxopyrrolidin-1-yl)propoxy, 2-(pyrrolidin-1-yl)ethoxy, 3-(pyrrolidin-1-yl)propoxy, 2-(2-(pyrrolidin-1-yl)ethoxy)ethoxy, 2-(2-(4-methylpiperazin-1-yl)ethoxy)ethoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-(methylpiperidino)ethoxy, 3-(methylpiperidino)propoxy, 2-(ethylpiperidino)ethoxy, 3-(ethylpiperidino)propoxy, 2-((2-methoxyethyl)piperidino)ethoxy, 3-((2-methoxyethyl)piperidino)propoxy, 2-((2-methylsulphonyl)ethylpiperidino)ethoxy, 3-((2-methylsulphonyl)ethylpiperidino)propoxy, piperidin-3-ylmethoxy, piperidin-4-ylmethoxy, 2-(piperidin-3-yl)ethoxy, 2-(piperidin-4-yl)ethoxy, 3-(piperidin-3-yl)propoxy, 3-(piperidin-4-yl)propoxy, 2-(methylpiperidin-3-yl)ethoxy, 2-(methylpiperidin-4-yl)ethoxy, 3-(methylpiperidin-3-yl)propoxy, 3-(methylpiperidin-4-yl)propoxy, 2-(ethylpiperidin-3-yl)ethoxy, 2-(ethylpiperidin-4-yl)ethoxy, 3-(ethylpiperidin-3-yl)propoxy, 3-(ethylpiperidin-4-yl)propoxy.

Sub
B2

4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline,
6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,
4-(5-(3-furyl)pyrazol-3-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
6-methoxy-7-(3-morpholinopropoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,
7-(2-(imidazol-1-yl)ethoxy)-6-methoxy-4-(5-phenylpyrazol-3-yloxy)quinazoline,
4-(5-(4-chlorophenyl)pyrazol-3-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,
6-methoxy-7-(2-methoxyethoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,
4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)-6-methoxy-7-(2-(1,2,3-triazol-1-yl)ethoxy)quinazoline and

4-(4-methoxyphenyl)pyrazol-3-yloxy)-6-methoxy-7-(1-(2-methylsulphonyl)ethyl)piperidin-4-ylmethoxy)quinazoline,
and salts thereof.

5 12. A compound as claimed in claim 4 selected from:

7-(2-methoxyethoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,
4-(5-(2-fluorophenyl)pyrazol-3-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
6-methoxy-7-(3-morpholinopropoxy)-4-(5-(3-nitrophenyl)pyrazol-3-yloxy)quinazoline,
6-methoxy-7-(3-morpholinopropoxy)-4-(5-(4-nitrophenyl)pyrazol-3-yloxy)quinazoline,
10 6-methoxy-7-(3-morpholinopropoxy)-4-(5-(4-pyridyl)pyrazol-3-yloxy)quinazoline,
4-(5-(4-fluorophenyl)pyrazol-3-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline, and
6-methoxy-7-(2-methoxyethoxy)-4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)quinazoline,
and salts thereof.

15 13. The use of a compound as claimed in claim 1 selected from:


6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(5-phenylpyrazol-3-ylamino)quinazoline
and
6,7-dimethoxy-4-(5-phenylpyrazol-3-yloxy)quinazoline
or a salt thereof, in the manufacture of a medicament for use in the production of an
20 antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals such as
humans.

14. A compound as claimed in any one of claims 4 to 12 in the form of a
pharmaceutically acceptable salt.

25


15. A process for the preparation of a compound of formula I or salt thereof
which comprises:

(a) the reaction of a compound of the formula III:



(III)


(wherein R^2 and m are as defined in claim 1 and L^1 is a displaceable moiety). with a compound of the formula IV:



(IV)

(wherein ring C, R^1 , Z and n are as defined in claim 1);

(b) compounds of formula I and salts thereof wherein at least one R^2 is R^5X^1 wherein R^5 is as defined in claim 1 and X^1 is -O-, -S-, -OCO- or -NR¹⁰- (wherein R^{10} independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) may be prepared by the reaction of a compound of the formula V:



(V)


(wherein ring C, Z, R^1 , R^2 and n are as defined in claim 1 and X^1 is as defined herein in this section and s is an integer from 0 to 2) with a compound of formula VI:



(VI)


(wherein R^5 is as defined in claim 1 and L^1 is as defined herein);

- 5 (c) compounds of the formula I and salts thereof wherein at least one R^2 is R^5X^1 wherein R^5 is as defined in claim 1 and X^1 is -O-, -S-, -OCO- or -NR¹⁰- (wherein R^{10} represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) may be prepared by the reaction of a compound of the formula VII:



(VII)

with a compound of the formula VIII:



(VIII)

(wherein R^1 , R^2 , R^5 , ring C, Z and n are as defined in claim 1 and s and L^1 are as defined herein and X^1 is as defined herein in this section);

- (d) compounds of the formula I and salts thereof wherein at least one R^2 is R^5X^1 wherein X^1 is as defined in claim 1 and R^5 is C₁₋₃alkylR⁶², wherein R^{62} is selected from one of the following nine groups:

1) X^{10} C₁₋₃alkyl (wherein X^{10} represents -O-, -S-, -SO₂-, -NR⁶³CO- or -NR⁶⁴SO₂- (wherein R^{63} and R^{64} which may be the same or different are each hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl);

- 2) NR⁶⁵R⁶⁶ (wherein R^{65} and R^{66} which may be the same or different are each hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl);

3) $X^{11}C_{1-3}alkylX^5R^{22}$ (wherein X^{11} represents -O-, -S-, -SO₂-, -NR⁶⁷CO-, -NR⁶⁸SO₂- or -NR⁶⁹- (wherein R⁶⁷, R⁶⁸, and R⁶⁹ which may be the same or different are each hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and X⁵ and R²² are as defined in claim 1);

4) R²⁸ (wherein R²⁸ is as defined in claim 1);

5) $X^{12}R^{29}$ (wherein X^{12} represents -O-, -S-, -SO₂-, -NR⁷⁰CO-, -NR⁷¹SO₂-, or -NR⁷²- (wherein R⁷⁰, R⁷¹, and R⁷² which may be the same or different are each hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁹ is as defined in claim 1);


6) $X^{13}C_{1-3}alkylR^{29}$, preferably $X^{13}C_{1-3}alkylR^{29}$, (wherein X^{13} represents -O-, -S-, -SO₂-, -NR⁷³CO-, -NR⁷⁴SO₂- or -NR⁷⁵- (wherein R⁷³, R⁷⁴ and R⁷⁵ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁹ is as defined in claim 1);

7) R²⁹ (wherein R²⁹ is as defined in claim 1);

8) $X^{14}C_{1-3}alkylR^{28}$ (wherein X^{14} represents -O-, -S-, -SO₂-, -NR⁷⁶CO-, -NR⁷⁷SO₂- or -NR⁷⁸- (wherein R⁷⁶, R⁷⁷ and R⁷⁸ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁸ is as defined in claim 1); and

9) $R^{54}C_{1-3}alkylX^9R^{55}$ (wherein R⁵⁴, R⁵⁵ and X⁹ are as defined in claim 1);

may be prepared by reacting a compound of the formula IX:



(IX)

(wherein X¹, R¹, R², ring C, Z and n are as defined in claim 1 and s and L¹ are as defined herein) with a compound of the formula X:



(X)

(wherein R⁶² is as defined herein);

- 5 (I) compounds of the formula I and salts thereof wherein X' is -SO- or -SO₂- may be prepared by oxidation from the corresponding compound in which X' is -S- or -SO-; and when a salt of a compound of formula I is required, reaction of the compound obtained with an acid or base whereby to obtain the desired salt.

- 10 16. A pharmaceutical composition which comprises as active ingredient a
compound of formula I or a pharmaceutically acceptable salt thereof as claimed in any one of
claims 4 to 12 in association with a pharmaceutically acceptable excipient or carrier.

17. A method for producing an antiangiogenic and/or vascular permeability
15 reducing effect in a warm-blooded animal in need of such treatment which comprises
administering to said animal an effective amount of a compound of formula I as defined in
claim 1 or a pharmaceutically acceptable salt thereof.

add
B4

add
B5